摘要 |
The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.; |
主权项 |
1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof; wherein:
n is 0 or 1;represents a single or double bond;X is carbon;Y, Z, and U are independently carbon or nitrogen; provided that, when Y is carbon and both Z and U are nitrogen, the bond between C6 and C7 is a double bond;R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of null, H, C1-6 alkyl, alkenyl, alkynyl, fluoroalkyl, chloroalkyl, bromoalkyl, iodoalkyl, perfluoroalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, heterocyclyl, acyl, aminocarbonyl, amino, hydroxyl, alkoxy, acyloxy, silyloxy, amido, carbamoyl, and sulfonamido; and R3 is optionally connected with R2 or R4 to form carbocycle or heterocycle. |